Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes:: Relevance to xenobiotic metabolism and toxicity

被引:237
作者
Wormhoudt, LW [1 ]
Commandeur, JNM [1 ]
Vermeulen, NPE [1 ]
机构
[1] Free Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Mol Toxicol, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands
关键词
genetic polymorphisms; biotransformation; enzymes; metabolism; toxicology; inter-individual variability;
D O I
10.1080/10408449991349186
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
In this review, an overview is presented of the current knowledge of genetic polymorphisms of four of the most important enzyme families involved in the metabolism of xenobiotics, that is, the N-acetyltransferase (NAT), cytochrome P450 (P450), glutathione-S-transferase (GST), and microsomal epoxide hydrolase (mEH) enzymes. The emphasis is on two main topics, the molecular genetics of the polymorphisms and the consequences for xenobiotic metabolism and toxicity. Studies are described in which wild-type and mutant alleles of biotransformation enzymes have been expressed in heterologous systems to study the molecular genetics and the metabolism and pharmacological or toxicological effects of xenobiotics. Furthermore, studies are described that have investigated the effects of genetic polymorphisms of biotransformation enzymes on the metabolism of drugs in humans and on the metabolism of genotoxic compounds in vivo as well. The effects of the polymorphisms are highly dependent on the enzyme systems involved and the compounds being metabolized. Several polymorphisms are described that also clearly influence the metabolism and effects of drugs and toxic compounds, in vivo in humans. Future perspectives in studies on genetic polymorphisms of biotransformation enzymes are also discussed. It is concluded that genetic polymorphisms of biotransformation enzymes are in a number of cases a major factor involved in the interindividual variability in xenobiotic metabolism and toxicity. This may lead to interindividual variability in efficacy of drugs and disease susceptibility.
引用
收藏
页码:59 / 124
页数:66
相关论文
共 531 条
  • [1] THE STRUCTURE AND CHARACTERISTICS OF A 4TH ALLELE OF POLYMORPHIC N-ACETYLTRANSFERASE GENE FOUND IN THE JAPANESE POPULATION
    ABE, M
    DEGUCHI, T
    SUZUKI, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 191 (03) : 811 - 816
  • [2] GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS
    AGUNDEZ, JAG
    MARTINEZ, C
    LEDESMA, MC
    LADONA, MG
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 412 - 417
  • [3] Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
  • [4] RELATIONSHIP OF N-DEMETHYLATION OF AMIFLAMINE AND ITS METABOLITE TO DEBRISOQUINE HYDROXYLATION POLYMORPHISM
    ALVAN, G
    GRIND, M
    GRAFFNER, C
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (04) : 515 - 519
  • [5] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
    ALVAN, G
    BECHTEL, P
    ISELIUS, L
    GUNDERTREMY, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
  • [6] CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG OXIDATION
    ALVAN, G
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (03) : 209 - 228
  • [7] ALVAN G, 1982, LANCET, V1, P333
  • [8] AMOS CI, 1992, CANCER EPIDEM BIOMAR, V1, P505
  • [9] POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS
    ANDERSSON, T
    REGARDH, CG
    LOU, YC
    ZHANG, Y
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 25 - 31
  • [10] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS
    ANDERSSON, T
    REGARDH, CG
    DAHLPUUSTINEN, ML
    BERTILSSON, L
    [J]. THERAPEUTIC DRUG MONITORING, 1990, 12 (04) : 415 - 416